These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 26411931)

  • 1. Evaluation of collected outcome measures in axial spondyloarthritis in daily-care rheumatology settings: the experience of the RHEVER network.
    Che H; Etcheto A; Dernis E; Nataf H; Boumier P; Breuillard P; Durandin-Truffinet M; Fechtenbaum J; Gaud-Listrat V; Giraud B; Hudry C; Labatide-Alanore S; Le Devic P; Le Goux P; Lebrun A; Maheu E; Moura B; Nguyen M; Sacchi A; Ayral X; Blanchais A; Neveu S; Dougados M; Moltó A
    Clin Exp Rheumatol; 2015; 33(6):851-7. PubMed ID: 26411931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Responsiveness of a simple RAPID-3-like index compared to disease-specific BASDAI and ASDAS indices in patients with axial spondyloarthritis.
    Castrejón I; Pincus T; Wendling D; Dougados M
    RMD Open; 2016; 2(2):e000235. PubMed ID: 27486525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors.
    Monti S; Todoerti M; Codullo V; Favalli EG; Biggioggero M; Becciolini A; Montecucco C; Caporali R
    Mod Rheumatol; 2018 May; 28(3):542-549. PubMed ID: 28880727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibromyalgia in Spondyloarthritis: Effect on Disease Activity Assessment in Clinical Practice.
    Wach J; Letroublon MC; Coury F; Tebib JG
    J Rheumatol; 2016 Nov; 43(11):2056-2063. PubMed ID: 27633820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.
    Pedersen SJ; Sørensen IJ; Hermann KG; Madsen OR; Tvede N; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen K; Johansen JS; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Skjødt T; Hansen A; Ostergaard M
    Ann Rheum Dis; 2010 Jun; 69(6):1065-71. PubMed ID: 19740906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brief Report: Clinical Course Over Two Years in Patients With Early Nonradiographic Axial Spondyloarthritis and Patients With Ankylosing Spondylitis Not Treated With Tumor Necrosis Factor Blockers: Results From the German Spondyloarthritis Inception Cohort.
    Poddubnyy D; Haibel H; Braun J; Rudwaleit M; Sieper J
    Arthritis Rheumatol; 2015 Sep; 67(9):2369-75. PubMed ID: 26017497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validity of the ankylosing spondylitis disease activity score (ASDAS) in patients with early spondyloarthritis from the Esperanza programme.
    Fernández-Espartero C; de Miguel E; Loza E; Tomero E; Gobbo M; Descalzo MA; Collantes-Estévez E; Mulero J; Muñoz-Fernández S; Zarco P; Carmona L;
    Ann Rheum Dis; 2014 Jul; 73(7):1350-5. PubMed ID: 23709245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Routine Assessment of Patient Index Data (RAPID3) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Scores Yield Similar Information in 85 Korean Patients With Ankylosing Spondylitis Seen in Usual Clinical Care.
    Park SH; Choe JY; Kim SK; Lee H; Castrejón I; Pincus T
    J Clin Rheumatol; 2015 Sep; 21(6):300-4. PubMed ID: 26308349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How to calculate the ASDAS based on C-reactive protein without individual questions from the BASDAI: the BASDAI-based ASDAS formula.
    Aranda-Valera IC; Garrido-Castro JL; Ladehesa-Pineda L; Vazquez-Mellado J; Zarco P; Juanola X; Gonzalez-Navas C; Font-Ugalde P; Castro-Villegas MC
    Rheumatology (Oxford); 2020 Jul; 59(7):1545-1549. PubMed ID: 31628804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A psychometric analysis of outcome measures in peripheral spondyloarthritis.
    Turina MC; Ramiro S; Baeten DL; Mease P; Paramarta JE; Song IH; Pangan AL; Landewé R
    Ann Rheum Dis; 2016 Jul; 75(7):1302-7. PubMed ID: 26245756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimisation of rheumatology assessments - the actual situation in axial spondyloarthritis including ankylosing spondylitis.
    Braun J; Kiltz U; Baraliakos X; van der Heijde D
    Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-96-104. PubMed ID: 25365096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease activity outcome measures are only available in half of the electronic medical files of patients with axial spondyloarthritis followed in an outpatient clinic: the results of an audit of a tertiary-care rheumatology department.
    Portier E; Dougados M; Moltó A
    Rheumatol Int; 2022 May; 42(5):825-829. PubMed ID: 34821969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BASDAI cut-off values corresponding to ASDAS cut-off values.
    Kwon OC; Park MC
    Rheumatology (Oxford); 2022 May; 61(6):2369-2374. PubMed ID: 34558610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors.
    Pedersen SJ; Sørensen IJ; Garnero P; Johansen JS; Madsen OR; Tvede N; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen K; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Skjødt T; Lambert R; Hansen A; Østergaard M
    Ann Rheum Dis; 2011 Aug; 70(8):1375-81. PubMed ID: 21551511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The adherence to ASAS classification criteria and to ASAS recommendations for the use of anti-TNH-alpha agents in axial spondyloarthritis.
    Spadaro A; Lubrano E; Marchesoni A; Cauli A; Cantini F; Carotti M; D'Angelo S; Grassi W; Lapadula G; Macchioni P; Mathieu A; Punzi L; Ramonda R; Salaffi F; Salvarani C; Scarpa R; Olivieri I
    Clin Exp Rheumatol; 2014; 32(4):465-70. PubMed ID: 24850468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy.
    Vastesaeger N; Cruyssen BV; Mulero J; Gratacós Masmitjá J; Zarco P; Almodovar R; Font P; Juanola X; Collantes-Estevez E;
    Reumatol Clin; 2014; 10(4):204-9. PubMed ID: 24598027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Compliance to treatment and effectiveness of therapy in different regimes of monitoring activity of patients with axial spondyloarthritis].
    Gaĭdukova IZ; Akulova AI; Aparkina AV; Rebrov AP
    Klin Med (Mosk); 2014; 92(10):60-5. PubMed ID: 25782323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis.
    Ciurea A; Scherer A; Weber U; Exer P; Bernhard J; Tamborrini G; Riek M; Müller RB; Weiss B; Nissen MJ; Kissling R; Michel BA; Finckh A;
    Ann Rheum Dis; 2016 Mar; 75(3):532-9. PubMed ID: 25667205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No deterioration in health-related quality of life in patients with axial spondyloarthritis followed for 5 years in ordinary outpatient clinics in the biological treatment era.
    Rohde G; Berg KH; Pripp AH; Prøven A; Haugeberg G
    Qual Life Res; 2020 Jan; 29(1):99-107. PubMed ID: 31559519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort.
    Ramiro S; van der Heijde D; van Tubergen A; Stolwijk C; Dougados M; van den Bosch F; Landewé R
    Ann Rheum Dis; 2014 Aug; 73(8):1455-61. PubMed ID: 24812292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.